EFFECTS OF HMG COA REDUCTASE INHIBITORS ON WARFARIN-BINDING

被引:4
作者
FEELY, J
OCONNOR, P
机构
[1] Department of Pharmacology and Therapeutics, Trinity College Medical School, St James’S Hospital, Dublin
来源
DRUG INVESTIGATION | 1991年 / 3卷 / 05期
关键词
D O I
10.1007/BF03259744
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
[No abstract available]
引用
收藏
页码:315 / 316
页数:2
相关论文
共 9 条
[1]  
Ahmad S., Lovastatin warfarin interaction, Archives of Internal Medicine, 150, (1990)
[2]  
Brers O., Jacobsen S., pH lability in serum during equilibrium dialysis, British Journal of Clinical Pharmacology, 20, pp. 85-88, (1985)
[3]  
East C., Alivizatos P.A., Grundy S.M., Jones P.H., Farmer J.A., Rhab-domyolysis in patients receiving lovastatin after cardiac transplantation, New England Journal of Medicine, 318, pp. 47-48, (1988)
[4]  
Grundy S.M., HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, New England Journal of Medicine, 319, pp. 24-32, (1988)
[5]  
LaRosa J.C., Pravastatin: a new hydrophilic HMG-CoA-reductase inhibitor, New advances in the control of lipid metabolism: focus on pravastatin, pp. 39-43, (1989)
[6]  
McTavish D., Sorkin E.M., Pravastatin: a review of its pharmacological properties and therapeutic potential in hyperchol-esterolaemia, Drugs, 42, 1, pp. 65-89, (1991)
[7]  
O'Connor P., Feely J., Shepherd J., Lipid lowering drugs, British Medical Journal, 300, pp. 667-672, (1990)
[8]  
Pan H.Y., Triscari J., de Vault A.R., Smith S.A., Wang-Iverson D., Et al., Pharmacokinetic interaction between propranolol and the HMG-Co A Reductase inhibitors pravastatin and lovastatin, British Journal of Clinical Pharmacology, 31, pp. 665-670, (1991)
[9]  
Todd P.A., Goa K.L., Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia, Drugs, 40, 4, pp. 583-607, (1990)